Chengdu Olymvax Biopharmaceuticals Inc.

SHSE:688319 Stock Report

Market Cap: CN¥4.3b

Chengdu Olymvax Biopharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Chengdu Olymvax Biopharmaceuticals's earnings have been declining at an average annual rate of -25.9%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 13.6% per year.

Key information

-25.9%

Earnings growth rate

-26.5%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate13.6%
Return on equity-1.6%
Net Margin-1.6%
Next Earnings Update29 Mar 2025

Recent past performance updates

Recent updates

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

Oct 09
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Stock Rockets 40% As Investors Are Less Pessimistic Than Expected

We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

Sep 30
We Think Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Has A Fair Chunk Of Debt

What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Jun 24
What Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 26% Share Price Gain Is Not Telling You

Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

May 28
Is There An Opportunity With Chengdu Olymvax Biopharmaceuticals Inc.'s (SHSE:688319) 27% Undervaluation?

Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Apr 18
Chengdu Olymvax Biopharmaceuticals Inc. (SHSE:688319) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Mar 26
These 4 Measures Indicate That Chengdu Olymvax Biopharmaceuticals (SHSE:688319) Is Using Debt Extensively

Revenue & Expenses Breakdown

How Chengdu Olymvax Biopharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SHSE:688319 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24530-9374134
30 Jun 24489-39357148
31 Mar 24500-12356144
31 Dec 2349618338115
30 Sep 2352917365132
30 Jun 2354824367132
31 Mar 2356137357124
31 Dec 2254727364122
30 Sep 225737036893
30 Jun 225519735865
31 Mar 224778131562
31 Dec 2148710830556
30 Sep 214057826846
30 Jun 213786525649
31 Mar 213285022545
31 Dec 203203622943
31 Dec 19179-3115344
31 Dec 1876-195531
30 Jun 186314470
31 Mar 18547460
31 Dec 17451450
30 Sep 1726-23500
30 Jun 177-48540
31 Mar 174-52550
31 Dec 160-56550
30 Sep 160-51520
30 Jun 160-47490
31 Mar 160-50510
31 Dec 150-52520
31 Dec 140-30260

Quality Earnings: 688319 is currently unprofitable.

Growing Profit Margin: 688319 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 688319 is unprofitable, and losses have increased over the past 5 years at a rate of 25.9% per year.

Accelerating Growth: Unable to compare 688319's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 688319 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (1.3%).

Return on Equity

High ROE: 688319 has a negative Return on Equity (-1.6%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/11 09:28
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Chengdu Olymvax Biopharmaceuticals Inc. is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pei ChengChina Galaxy Securities Co., Ltd.
Yupeng JiaoChina Merchants Securities Co. Ltd.
Feifei XuChina Merchants Securities Co. Ltd.